11 June 2021
The combination of AXL inhibitor bemcentinib and low-dose cytarabine is well tolerated and efficacious in elderly relapsed AML patients: Update from the ongoing BGBC003 Phase II trial (NCT02488408)
Selective AXL inhibitors
Footer
Selective AXL inhibitors
11 June 2021
The combination of AXL inhibitor bemcentinib and low-dose cytarabine is well tolerated and efficacious in elderly relapsed AML patients: Update from the ongoing BGBC003 Phase II trial (NCT02488408)